ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

•This ESMO Clinical Practice Guideline eUpdate addresses developments in first-line therapy in advanced urothelial carcinoma.•Enfortumab vedotin–pembrolizumab (EV–P) is the new standard of care in first-line advanced urothelial carcinoma.•Nivolumab–cisplatin–gemcitabine or platinum-based ChT and mai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2024-06, Vol.35 (6), p.485-490
Hauptverfasser: Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B.P., Ravaud, A., Shariat, S.F., Szabados, B., van der Heijden, M.S., Gillessen, S.
Format: Artikel
Sprache:eng
Schlagworte:
bladder cancer
enfortumab vedotin
fibroblast growth factor receptor inhibitor
nivolumab
pembrolizumab
urothelial carcinoma
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•This ESMO Clinical Practice Guideline eUpdate addresses developments in first-line therapy in advanced urothelial carcinoma.•Enfortumab vedotin–pembrolizumab (EV–P) is the new standard of care in first-line advanced urothelial carcinoma.•Nivolumab–cisplatin–gemcitabine or platinum-based ChT and maintenance avelumab are alternatives if EV–P is not possible.
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2024.03.001